COGENT BIOSCIENCES, INC.

(COGT)
  Report
Real-time Estimate Cboe BZX  -  12:50 2022-08-19 pm EDT
15.08 USD   -0.79%
08/18Guggenheim Adjusts Cogent Biosciences Price Target to $22 From $18, Maintains Buy Rating
MT
08/09Wedbush Adjusts Cogent Biosciences Price Target to $20 From $17, Maintains Outperform Rating
MT
08/09COGENT BIOSCIENCES : Reports Recent Business Highlights and Second Quarter 2022 Financial Results - Form 8-K
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/15/2022 08/16/2022 08/17/2022 08/18/2022 08/19/2022 Date
14.61(c) 14.16(c) 15.76(c) 15.2(c) 15.165 Last
1 462 038 1 083 158 4 571 553 2 210 976 612 633 Volume
+3.40% -3.08% +11.30% -3.55% -0.23% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -140 M - -
Net Debt 2022 - - -
P/E ratio 2022 -6,43x
Yield 2022 -
Sales 2023 - - -
Net income 2023 -164 M - -
Net Debt 2023 - - -
P/E ratio 2023 -7,41x
Yield 2023 -
Capitalization 1 000 M 1 000 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 77
Free-Float 100,0%
More Financials
Company
Cogent Biosciences, Inc. is a biotechnology company that is focused on developing precision therapies for genetically defined diseases. The Company’s most advanced clinical program, bezuclastinib (CGT9486), is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a... 
More about the company
Ratings of Cogent Biosciences, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about COGENT BIOSCIENCES, INC.
08/18Guggenheim Adjusts Cogent Biosciences Price Target to $22 From $18, Maintains Buy Ratin..
MT
08/09Wedbush Adjusts Cogent Biosciences Price Target to $20 From $17, Maintains Outperform R..
MT
08/09COGENT BIOSCIENCES : Reports Recent Business Highlights and Second Quarter 2022 Financial ..
PU
08/09Cogent Biosciences Q2 Loss Widens
MT
08/09COGENT BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
08/09Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2022 Financial..
AQ
08/09Cogent Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months..
CI
08/08SVB Financial Adjusts Cogent Biosciences Price Target to $20 From $15, Maintains Outper..
MT
07/31Life Raft Group Holds Biennial Life Fest Convention July 29-31
AQ
07/07COGENT BIOSCIENCES : Bezuclastinib Selectivity to KIT A Loop Mutations, Minimal Brain Pene..
PU
06/28Guggenheim Starts Cogent Biosciences at Buy With $15 Price Target
MT
06/24COGENT BIOSCIENCES, INC.(NASDAQGS : COGT) dropped from Russell 2500 Growth Index
CI
06/24COGENT BIOSCIENCES, INC.(NASDAQGS : COGT) dropped from Russell Microcap Growth Index
CI
06/24COGENT BIOSCIENCES, INC.(NASDAQGS : COGT) dropped from Russell 3000E Growth Index
CI
06/24COGENT BIOSCIENCES, INC.(NASDAQGS : COGT) dropped from Russell 3000 Growth Index
CI
More news
News in other languages on COGENT BIOSCIENCES, INC.
08/09La perte de Cogent Biosciences au deuxième trimestre s'accentue
08/09Cogent Biosciences, Inc. annonce ses résultats pour le deuxième trimestre et le semestr..
06/14Cogent lance une offre élargie d'actions ordinaires et de bons de souscription pour un ..
06/13Cogent Biosciences lance une offre d'actions ordinaires de 125 millions de dollars
06/10MISE À JOUR SECTORIELLE : Les actions du secteur de la santé restent en baisse en fin de j..
More news
Analyst Recommendations on COGENT BIOSCIENCES, INC.
More recommendations
Chart COGENT BIOSCIENCES, INC.
Duration : Period :
Cogent Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COGENT BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 15,20 $
Average target price 21,67 $
Spread / Average Target 42,5%
EPS Revisions
Managers and Directors
Andrew R. Robbins President, Chief Executive Officer & Director
John L. Green Chief Financial & Accounting Officer
Peter Harwin Chairman
Jessica Sachs Vice President-Clinical Sciences
Brad Barnett Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
COGENT BIOSCIENCES, INC.77.16%1 000
GILEAD SCIENCES, INC.-10.23%81 694
VERTEX PHARMACEUTICALS34.01%75 473
REGENERON PHARMACEUTICALS, INC.-1.06%66 800
WUXI APPTEC CO., LTD.-23.44%38 898
BIONTECH SE-42.74%35 872